Papulopustular Rosacea Clinical Trial
Official title:
Safety and Efficacy of Rifaximin Delayed Release 400 mg Tablets in Patients With Moderate-to-severe Papulopustular Rosacea and Positive Lactulose Breath Test. A Multicenter Double-blind, Placebo-controlled Randomized Clinical Trial
Preliminary evidence suggests that treatment with rifaximin may be beneficial in patients
with papulopustular rosacea.
The present clinical trial is aimed to investigate the safety and efficacy of oral rifaximin
delayed release versus placebo in adults with moderate-to-severe papulopustular rosacea
(a.k.a. subtype II) and positive lactulose H2/CH4 breath test.
Status | Recruiting |
Enrollment | 236 |
Est. completion date | October 2020 |
Est. primary completion date | April 2020 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 70 Years |
Eligibility |
Key inclusion Criteria: 1. Men and women aged 18 to 70 years at screening. 2. Female participants are eligible if they are either of non-childbearing potential or of childbearing potential with a negative pregnancy test result at screening and randomization and agreeing to use a highly effective method of contraception until 72 hours after taking the last study treatment dose. 3. Moderate-to-severe papulopustular rosacea (a.k.a. subtype II, RII) at screening and confirmed at randomization. Moderate-to-severe rosacea is defined as the presence of 11 or more facial papules or pustules with or without plaques. 4. Positivity of lactulose H2/CH4 breath test (L-BT) within the last 2-weeks before randomization. 5. Patients accepting to provide and legally capable of providing free and informed consent to all procedures included in the protocol (including facial skin photography). Key exclusion Criteria: 1. Granulomatous rosacea or rosacea fulminans. 2. Erythematoteleangectatic, phymatous or ocular rosacea only. Patients with these subtypes associated with papulopustular rosacea can be enrolled. 3. Circulating anti-helicobacter pylori IgM and/or IgG at screening (V1). 4. Positivity at the faecal Clostridium Difficile toxin assay at screening (V1). 5. History or family history of inflammatory bowel disease (Crohn's disease or ulcerative colitis) or other conditions characterized by severe intestinal ulcers. 6. History or family history of coeliac disease. 7. Patients with intestinal obstruction or partial intestinal obstruction. 8. Presence of diarrhoea associated with fever and/or blood in the stool. 9. Health conditions requiring continuous or intermittent treatment with facial topical, inhaled or systemic steroids and/or biologic or non-biologic immunosuppressive or immunomodulatory agents (e.g. autoimmune diseases, etc.). 10. Severe kidney impairment (i.e. estimated glomerular filtration rate <30 ml/min). 11. Severe hepatic impairment (i.e. Child-Pugh B or C). 12. Cancer or any cancer-related treatment within 5 years prior to screening (excluding non-melanoma skin-cancer). 13. History of alcohol or drug abuse within a year prior to screening. 14. Facial skin conditions that can interfere with reliable assessment of rosacea throughout the study (e.g. keloids, hypertrophic scarring, recent facial surgery etc.) 15. Any other significant health condition (e.g. cardiovascular, respiratory, renal, hepatic, neurologic, psychiatric, hematologic, oncologic, immune etc.) that in the investigator's judgement may: i) jeopardize the patient's safe participation in the trial or ii) make unlikely the patient's completion of the study or iii) make unlikely the patient's compliance with the study procedures (e.g. highly anticipated need of non-permitted treatments, terminal illness, etc.). 16. History of hypersensitivity to rifaximin, rifamycin-derivatives, any of the rifaximin-EIR excipients, or any UV protection cream component. 17. Treatment with biologic immunomodulatory and/or immunosuppressive drugs (e.g. anti-TNF drugs) within 6 months prior to randomization. 18. Treatment with non-biologic immunomodulatory and/or immunosuppressive drugs (e.g. cyclosporine, methotrexate etc.) within 30 days prior to randomization. 19. Treatment with warfarin within 14 days prior to randomization. 20. Treatment with niacin within 30 days prior to randomization. 21. Topical facial or systemic antibiotics within 30 days before randomization; 22. Treatment with neomycin or other low-absorbable oral antibiotics (such as marketed rifaximin) within 90 days before randomization. 23. Topical facial, inhaled or systemic corticosteroids within 30 days prior to randomization. 24. Topical facial retinoids within 30 days before randomization. 25. Systemic retinoids within 6 months before randomization. 26. Any other topical or systemic treatment for rosacea within 30 days before randomization (including also laser and pulsed light, etc.). 27. Pharmaceutical prebiotics and probiotics (functional food is allowed), within 30 days before randomization. 28. Any experimental treatment within 6 months prior to randomization. 29. Women who are pregnant, breast-feeding or planning a pregnancy during the trial period. |
Country | Name | City | State |
---|---|---|---|
Italy | Ospedali Riuniti di Ancona | Ancona | |
Italy | Policlinico di Bari | Bari | |
Italy | Policlinico Sant'Orsola Malpighi | Bologna | |
Italy | Spedali Civili | Brescia | |
Italy | Policlinico Vittorio Emanuele | Catania | |
Italy | Ospedale Policlinico San Martino | Genova | |
Italy | Ospedale della Misericordia | Grosseto | |
Italy | Policlinico di Modena | Modena | |
Italy | Azienda Ospedaliera Universitaria Federico II | Napoli | |
Italy | Policlinico Universitario A. Gemelli | Roma | |
Italy | Azienda Ospedaliera Santa Maria | Terni | |
Italy | A.O.U. Città della Salute e della Scienza | Torino |
Lead Sponsor | Collaborator |
---|---|
Alfasigma S.p.A. |
Italy,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Mean change from Baseline (day 1) in circulating inflammatory marker levels at 10 ± 1, day 30 ± 1 and day 60 ± 3 | change respect to baseline | 10, 30 and 60 days | |
Other | Mean change from baseline (day 1) skin texture index at 10 ± 1, day 30 ± 1 and day 60 ± 3 as provided by Canfield Image Analysis | change respect to baseline | 10, 30 and 60 days | |
Primary | Mean change from baseline (day 1) in number of rosacea inflammatory lesions (papules, pustules or plaques) at the end of treatment visit (day 30 ± 1) | changes in number of lesions | 30 days | |
Primary | Percent of participants showing treatment success (IGA score of 0 [clear] or 1 [almost clear]) at the end of treatment visit (day 30 ± 1) | per cent changes in IGA score 0 and 1 patients | 30 days | |
Secondary | Mean change from Baseline (day 1) in number of rosacea inflammatory lesions at the end of treatment visit (day 30 ± 1) as provided by Canfield Image Analysis | changes respect to baseline | 30 days | |
Secondary | Mean change from Baseline (day 1) in number of inflammatory lesions (papules, pustules or plaques) at day 10 ± 1 and day 60 ± 3 | change respect to baseline | 10 and 60 days | |
Secondary | Percent of participants showing treatment success (i.e. IGA score of 0 or 1) at day 10 ± 1 and day 60 ± 3 | per cent changes in IGA score 0 and 1 patients | 10 and 60 days | |
Secondary | Percent of participants with IGA score of 0 (clear) at day 10 ± 1, day 30 ± 1 and day 60 ± 3 | per cent changes in IGA score 0 patients | 10, 30 and 60 days | |
Secondary | Mean change from Baseline (day 1) in the following rosacea additional features at day 10 ± 1, day 30 ± 1 and day 60 ± 3: • burning or stinging • telangiectasia • ocular manifestations • phymatous changes | change respect to baseline | 10, 30 and 60 days | |
Secondary | Mean change from Baseline (day 1) in facial non-transient erythema at day 10 ± 1, day 30 ± 1 and day 60 ± 3 (absent=0, mild=1, moderate=2, severe=3) | change respect to baseline | 10, 30 and 60 days | |
Secondary | Mean change from Baseline (day 1) in number of inflammatory lesions at day 10 ± 1 and day 60 ± 3 as provided by Canfield Image Analysis | change respect to baseline | 10 and 60 days | |
Secondary | Mean change from Baseline (day 1) in facial non-transient erythema score at day 10 ± 1, day 30 ± 1 and day 60 ± 3, based on global fractional area redness as provided by Canfield Image Analysis | change respect to baseline | 10, 30 and 60 days | |
Secondary | Mean change from Baseline in Basic Self-Esteem Scale at day 30 ± 1 and day 60 ± 3 | change respect to previous evaluation | 30 and 60 days | |
Secondary | Mean change from Baseline (day 1) in Dermatology Life Quality Index (10-item DLQI) at day 30 ± 1 and day 60 ± 3 | change respect to baseline | 30 and 60 days | |
Secondary | Mean difference in Treatment Satisfaction Questionnaire between study groups at day 30 ± 1 | differences between treatment arms | 30 days |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03276936 -
A Study to Evaluate the Long-Term Safety of Topical Administration of FMX103 in the Treatment of Moderate to Severe Papulopustular Rosacea
|
Phase 3 | |
Completed |
NCT02601963 -
Safety and Efficacy Study of a Topical Minocycline Foam in Patients With Papulopustular Rosacea
|
Phase 2 | |
Completed |
NCT02268474 -
Excel V 532 nm KTP Laser for Treatment of Erythematotelangiectatic Rosacea & Papulopustular Rosacea
|
N/A | |
Completed |
NCT01555463 -
Safety and Efficacy of Azelaic Acid Foam, 15 % in Papulopustular Rosacea
|
Phase 3 | |
Active, not recruiting |
NCT03667222 -
Topical Minocycline Gel for Inflammatory Lesions of Papulopustular Rosacea
|
Phase 2 | |
Terminated |
NCT03564145 -
A Long-Term Safety Study of S5G4T-1 in the Treatment of Papulopustular Rosacea
|
Phase 3 | |
Completed |
NCT05150587 -
Safety, Efficacy and Pharmacokinetics of Rifaximin in Patients With Moderate-to-severe Papulopustular Rosacea
|
Phase 2 | |
Completed |
NCT03263273 -
Study to Evaluate the Safety and Efficacy of Topical Minocycline Gel in Patients With Papulopustular Rosacea
|
Phase 2 | |
Completed |
NCT05343455 -
A Study to Assess the Safety, Efficacy and Tolerability of Oral DFD-29 Capsules for the Treatment of Rosacea (MVOR-2)
|
Phase 3 | |
Completed |
NCT01784133 -
A Twelve Week Safety and Efficacy Study in Rosacea
|
Phase 2 | |
Completed |
NCT01872715 -
Patient Centered Outcomes in Rosacea: An Exploratory Multi-media Analysis of the Patient Experience on Oracea
|
Phase 4 | |
Completed |
NCT05296629 -
A Randomized, Double-Blind Study to Assess the Safety, Efficacy and Tolerability of Oral DFD-29 Capsules for the Treatment of Rosacea.
|
Phase 3 | |
Completed |
NCT05838170 -
Study of TP-04 in Participants With Papulopustular Rosacea
|
Phase 2 | |
Recruiting |
NCT06013371 -
PDE4 Inhibition in Seborrheic Dermatitis and Papulopustular Rosacea
|
Phase 2 | |
Completed |
NCT03564119 -
A Study of S5G4T-1 in the Treatment of Papularpustular Rosacea
|
Phase 3 | |
Completed |
NCT03079531 -
Open Label Study to Assess the Effect of Secukinumab in Moderate to Severe Papulopustular Rosacea
|
Phase 1/Phase 2 | |
Completed |
NCT01045551 -
Open Label Pilot Study of Apremilast in Treatment of Rosacea
|
Phase 2 | |
Completed |
NCT03448939 -
A Study of S5G4T-1 in the Treatment of Papulopustular Rosacea
|
Phase 3 | |
Completed |
NCT05675501 -
Evaluation of Topical Encapsulated Benzoyl Peroxide on the Skin Microbiome and Skin Biophysical Properties
|
Phase 1 | |
Withdrawn |
NCT03883945 -
A Safety and Efficacy Study to Evaluate Rosacea
|
Phase 1/Phase 2 |